Time Frame |
All Adverse Events (AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events (SAEs) considered to be treatment related for up to 5 years after stopping study treatment
|
Adverse Event Reporting Description |
Adverse events number at risk reflects the number of patients who received treatment and submitted at least one adverse event form.
|
|
Arm/Group Title
|
Arm I (Paclitaxel and Cisplatin)
|
Arm II (Paclitaxel, Cisplatin, Bevacizumab)
|
Arm III (Topotecan Hydrochloride and Paclitaxel)
|
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)
|
Arm/Group Description |
Paclitaxel 135 mg/m2 IV over 24 hrs...
|
Paclitaxel 135 mg/m2 IV over 24 hrs...
|
Paclitaxel 175 mg/m2 over 3 hrs on ...
|
Paclitaxel 175 mg/m2 over 3 hrs on ...
|
Arm/Group Description |
Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity
|
Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity
|
Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity
|
Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity
|
|
|
Arm I (Paclitaxel and Cisplatin)
|
Arm II (Paclitaxel, Cisplatin, Bevacizumab)
|
Arm III (Topotecan Hydrochloride and Paclitaxel)
|
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
--/-- |
--/-- |
--/-- |
--/-- |
|
|
Arm I (Paclitaxel and Cisplatin)
|
Arm II (Paclitaxel, Cisplatin, Bevacizumab)
|
Arm III (Topotecan Hydrochloride and Paclitaxel)
|
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
42/112 (37.50%) |
53/111 (47.75%) |
37/107 (34.58%) |
61/109 (55.96%) |
Blood and lymphatic system disorders |
|
|
|
|
Neutrophils |
2/112 (1.79%) |
2/111 (1.80%) |
3/107 (2.80%) |
1/109 (0.92%) |
Platelets |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
0/109 (0.00%) |
Blood/Bone Marrow - Other |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Leukocytes |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Hemoglobin |
1/112 (0.89%) |
3/111 (2.70%) |
0/107 (0.00%) |
1/109 (0.92%) |
Cardiac disorders |
|
|
|
|
Vasovagal Episode |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Supraventricular Tachycardia |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Cardiac Ischemia/Infarction |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Hypertension |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hypotension |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Gastrointestinal disorders |
|
|
|
|
Proctitis |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
2/109 (1.83%) |
Perforation, Gi - Colon |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Fistula, Gi - Small Bowel Nos |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Fistula, Gi - Rectum |
0/112 (0.00%) |
3/111 (2.70%) |
0/107 (0.00%) |
2/109 (1.83%) |
Obstruction, Gi - Colon |
0/112 (0.00%) |
2/111 (1.80%) |
1/107 (0.93%) |
1/109 (0.92%) |
Hemorrhoids |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Ulcer,gi - Rectum |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Perforation, Gi - Rectum |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dental: Teeth |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Leak, Gi - Rectum |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Ileus |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Obstruction, Gi - Gallbladder |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Obstruction, Gi - Small Bowel Nos |
2/112 (1.79%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Perforation, Gi - Small Bowel Nos |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Vomiting |
3/112 (2.68%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Anorexia |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dehydration |
0/112 (0.00%) |
3/111 (2.70%) |
0/107 (0.00%) |
2/109 (1.83%) |
Constipation |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Nausea |
2/112 (1.79%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Perforation, Gi - Ileum |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Diarrhea |
2/112 (1.79%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
General disorders |
|
|
|
|
Fever |
1/112 (0.89%) |
1/111 (0.90%) |
2/107 (1.87%) |
0/109 (0.00%) |
Fatigue |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Death No Ctcae Term - Disease Progression Nos |
1/112 (0.89%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Death No Ctcae Term - Sudden Death |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain - Other |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Pelvis |
0/112 (0.00%) |
3/111 (2.70%) |
1/107 (0.93%) |
0/109 (0.00%) |
Pain: Chest /Thorax Nos |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Pleura |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Neck |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Extremity-Limb |
1/112 (0.89%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Back |
2/112 (1.79%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Bone |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Pain: Rectum |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Abdominal Pain Nos |
4/112 (3.57%) |
4/111 (3.60%) |
2/107 (1.87%) |
6/109 (5.50%) |
Pain: Tumor |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Death No Ctcae Term - Multi-Organ Failure |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hepatobiliary disorders |
|
|
|
|
Cholecystitis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Immune system disorders |
|
|
|
|
Allergic Reaction/Hypersensitivity |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Infections and infestations |
|
|
|
|
Inf W/Gr 3 Or 4 Anc: Blood |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Skin (Cellulitis) |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Lung(Pneumonia) |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Blood |
0/112 (0.00%) |
0/111 (0.00%) |
2/107 (1.87%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis) |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Catheter-Related |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Febrile Neutropenia |
3/112 (2.68%) |
1/111 (0.90%) |
5/107 (4.67%) |
5/109 (4.59%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Urinary Tract Nos |
3/112 (2.68%) |
0/111 (0.00%) |
1/107 (0.93%) |
4/109 (3.67%) |
Inf Unknown Anc: Blood |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Infection - Other |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Colitis, Infectious (Eg.C. Difficile) |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Oral Cavity-Gums |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Abdomen Nos |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf Unknown Anc: Pelvis Nos |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf Unknown Anc: Urinary Tract Nos |
1/112 (0.89%) |
2/111 (1.80%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf Unknown Anc: Kidney |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf Unknown Anc: Bladder (Urinary) |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf Unknown Anc: Peritoneal Cavity |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf Unknown Anc: Skin (Cellulitis) |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Lung (Pneumonia) |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Gr 3 Or 4 Anc: Nerve-Peripheral |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Bladder |
2/112 (1.79%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Urinary Tract Nos |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Catheter-Related |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Metabolism and nutrition disorders |
|
|
|
|
Metabolic/Laboratory - Other |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Creatinine |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hyponatremia |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
Muscle Weakness - Left-Sided |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Nervous system disorders |
|
|
|
|
Syncope |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Involuntary Movement |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Neurology - Other |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Mental Status |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Mood Alteration - Depression |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Seizure |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Leukoencephalopathy |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cognitive Disturbance |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dizziness |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Renal and urinary disorders |
|
|
|
|
Renal/Genitourinary - Other |
1/112 (0.89%) |
0/111 (0.00%) |
2/107 (1.87%) |
0/109 (0.00%) |
Stricture, Anastomotic, Gu - Ureter |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cystitis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Urinary Retention |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Obstruction, Gu - Ureter |
1/112 (0.89%) |
0/111 (0.00%) |
2/107 (1.87%) |
1/109 (0.92%) |
Fistula, Gu - Vagina |
2/112 (1.79%) |
2/111 (1.80%) |
0/107 (0.00%) |
2/109 (1.83%) |
Fistula, Gu - Genital Tract-Female |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Fistula, Gu - Bladder |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Bladder Spasm |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Renal Failure |
3/112 (2.68%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
Pulmonary: Other |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Nasal/Paranasal Reactions |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pneumothorax |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Ards |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pleural Effusion |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dyspnea |
0/112 (0.00%) |
1/111 (0.90%) |
2/107 (1.87%) |
1/109 (0.92%) |
Skin and subcutaneous tissue disorders |
|
|
|
|
Dermatology/Skin - Other |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Ulceration |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vascular disorders |
|
|
|
|
Inr |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dic |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage, Gu - Urinary Nos |
1/112 (0.89%) |
2/111 (1.80%) |
1/107 (0.93%) |
3/109 (2.75%) |
Hemorrhage, Gu - Vagina |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage/Pulmonary - Larynx |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage, Gi - Rectum |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Hemorrhage, Gi - Upper Gi Nos |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage/Pulmonary - Nose |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Hemorrhage, Gi - Esophagus |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage, Gu - Ureter |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage, Gu - Bladder |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Thrombosis/Embolism (Vascular Access-Related) |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Thrombosis/Thrombus/Embolism |
7/112 (6.25%) |
8/111 (7.21%) |
3/107 (2.80%) |
3/109 (2.75%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, CTCAE (3.0)
|
|
Frequency Threshold for Reporting Other Adverse Events
|
0%
|
|
Arm I (Paclitaxel and Cisplatin)
|
Arm II (Paclitaxel, Cisplatin, Bevacizumab)
|
Arm III (Topotecan Hydrochloride and Paclitaxel)
|
Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)
|
|
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Affected / at Risk (%) |
Total |
112/112 (100.00%) |
111/111 (100.00%) |
107/107 (100.00%) |
107/109 (98.17%) |
Blood and lymphatic system disorders |
|
|
|
|
Neutrophils |
79/112 (70.54%) |
90/111 (81.08%) |
75/107 (70.09%) |
93/109 (85.32%) |
Platelets |
39/112 (34.82%) |
55/111 (49.55%) |
45/107 (42.06%) |
61/109 (55.96%) |
Blood/Bone Marrow - Other |
1/112 (0.89%) |
2/111 (1.80%) |
2/107 (1.87%) |
3/109 (2.75%) |
Leukocytes |
88/112 (78.57%) |
95/111 (85.59%) |
89/107 (83.18%) |
99/109 (90.83%) |
Lymphopenia |
4/112 (3.57%) |
12/111 (10.81%) |
8/107 (7.48%) |
13/109 (11.93%) |
Hemoglobin |
107/112 (95.54%) |
101/111 (90.99%) |
104/107 (97.20%) |
101/109 (92.66%) |
Lymphatics - Other |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Edema: Trunk/Genital |
2/112 (1.79%) |
0/111 (0.00%) |
2/107 (1.87%) |
1/109 (0.92%) |
Edema: Limb |
26/112 (23.21%) |
15/111 (13.51%) |
23/107 (21.50%) |
19/109 (17.43%) |
Edema: Head And Neck |
2/112 (1.79%) |
1/111 (0.90%) |
2/107 (1.87%) |
1/109 (0.92%) |
Dermal Change |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cardiac disorders |
|
|
|
|
Palpitations |
2/112 (1.79%) |
3/111 (2.70%) |
3/107 (2.80%) |
1/109 (0.92%) |
Ventricular Arrhythmia - Tachycardia |
2/112 (1.79%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
S/N Arrhythmia: Sinus Tachycardia |
3/112 (2.68%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vasovagal Episode |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Supraventricular Tachycardia |
0/112 (0.00%) |
0/111 (0.00%) |
2/107 (1.87%) |
0/109 (0.00%) |
S/N Arrhythmia: Sinus Bradycardia |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hypertension |
10/112 (8.93%) |
36/111 (32.43%) |
3/107 (2.80%) |
27/109 (24.77%) |
Left Venticular Diastolic Dysfunction |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cardiac General - Other |
2/112 (1.79%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pericardial Effusion |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hypotension |
3/112 (2.68%) |
3/111 (2.70%) |
3/107 (2.80%) |
2/109 (1.83%) |
Ear and labyrinth disorders |
|
|
|
|
Auditory/Ear - Other |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hearing (Without Monitoring Program) |
1/112 (0.89%) |
3/111 (2.70%) |
1/107 (0.93%) |
1/109 (0.92%) |
Tinnitus |
17/112 (15.18%) |
7/111 (6.31%) |
3/107 (2.80%) |
5/109 (4.59%) |
Hearing (Monitoring Program) |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Endocrine disorders |
|
|
|
|
Hot Flashes |
14/112 (12.50%) |
12/111 (10.81%) |
11/107 (10.28%) |
13/109 (11.93%) |
Diabetes |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Adrenal Insufficiency |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
0/109 (0.00%) |
Endocrine - Other |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hypothyroidism |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Eye disorders |
|
|
|
|
Ocular/Visual - Other |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Retinal Detachment |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Watery Eye |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Dry Eye |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Ocular Surface Disease |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Flashing Lights/Floaters |
2/112 (1.79%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Diplopia |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Blurred Vision |
10/112 (8.93%) |
7/111 (6.31%) |
4/107 (3.74%) |
10/109 (9.17%) |
Gastrointestinal disorders |
|
|
|
|
Fistula, Gi - Colon/Cecum/Appendix |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Obstruction, Gi - Ileum |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Proctitis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
4/109 (3.67%) |
Ulcer,gi - Anus |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Salivary Gland Changes |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Flatulence |
3/112 (2.68%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Ulcer,gi - Esophagus |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Dental: Periodontal |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Fistula, Gi - Small Bowel Nos |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Fistula, Gi - Rectum |
0/112 (0.00%) |
5/111 (4.50%) |
0/107 (0.00%) |
4/109 (3.67%) |
Obstruction, Gi - Colon |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Gastritis |
2/112 (1.79%) |
3/111 (2.70%) |
0/107 (0.00%) |
3/109 (2.75%) |
Esophagitis |
2/112 (1.79%) |
3/111 (2.70%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhoids |
1/112 (0.89%) |
7/111 (6.31%) |
1/107 (0.93%) |
3/109 (2.75%) |
Ulcer,gi - Rectum |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Heartburn |
7/112 (6.25%) |
18/111 (16.22%) |
8/107 (7.48%) |
4/109 (3.67%) |
Mucositis (Functional/Sympt) - Esophagus |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Dental: Teeth |
1/112 (0.89%) |
3/111 (2.70%) |
1/107 (0.93%) |
1/109 (0.92%) |
Mucositis (Functional/Sympt) - Pharynx |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Ileus |
0/112 (0.00%) |
3/111 (2.70%) |
1/107 (0.93%) |
1/109 (0.92%) |
Dysphagia |
2/112 (1.79%) |
5/111 (4.50%) |
0/107 (0.00%) |
1/109 (0.92%) |
Distention |
1/112 (0.89%) |
5/111 (4.50%) |
2/107 (1.87%) |
0/109 (0.00%) |
Taste Alteration |
10/112 (8.93%) |
11/111 (9.91%) |
9/107 (8.41%) |
13/109 (11.93%) |
Incontinence, Anal |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dry Mouth |
2/112 (1.79%) |
3/111 (2.70%) |
2/107 (1.87%) |
5/109 (4.59%) |
Mucositis (Functional/Sympt) - Oral Cavity |
7/112 (6.25%) |
6/111 (5.41%) |
3/107 (2.80%) |
10/109 (9.17%) |
Obstruction, Gi - Small Bowel Nos |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Colitis |
1/112 (0.89%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Mucositis (Clinical Exam) - Rectum |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Obstruction, Gi - Jejunum |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dentures |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Mucositis (Clinical Exam) - Oral Cavity |
7/112 (6.25%) |
7/111 (6.31%) |
8/107 (7.48%) |
10/109 (9.17%) |
Vomiting |
37/112 (33.04%) |
47/111 (42.34%) |
30/107 (28.04%) |
28/109 (25.69%) |
Anorexia |
30/112 (26.79%) |
42/111 (37.84%) |
27/107 (25.23%) |
33/109 (30.28%) |
Dehydration |
6/112 (5.36%) |
12/111 (10.81%) |
4/107 (3.74%) |
3/109 (2.75%) |
Constipation |
62/112 (55.36%) |
54/111 (48.65%) |
49/107 (45.79%) |
52/109 (47.71%) |
Nausea |
77/112 (68.75%) |
75/111 (67.57%) |
56/107 (52.34%) |
63/109 (57.80%) |
Gastrointestinal - Other |
3/112 (2.68%) |
4/111 (3.60%) |
1/107 (0.93%) |
2/109 (1.83%) |
Diarrhea |
38/112 (33.93%) |
46/111 (41.44%) |
39/107 (36.45%) |
35/109 (32.11%) |
General disorders |
|
|
|
|
Constitutional Symptoms - Other |
2/112 (1.79%) |
1/111 (0.90%) |
2/107 (1.87%) |
1/109 (0.92%) |
Sweating |
9/112 (8.04%) |
3/111 (2.70%) |
5/107 (4.67%) |
4/109 (3.67%) |
Weight Gain |
3/112 (2.68%) |
5/111 (4.50%) |
6/107 (5.61%) |
9/109 (8.26%) |
Patient Odor |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Fever |
16/112 (14.29%) |
17/111 (15.32%) |
13/107 (12.15%) |
16/109 (14.68%) |
Weight Loss |
9/112 (8.04%) |
26/111 (23.42%) |
6/107 (5.61%) |
19/109 (17.43%) |
Rigors/Chills |
7/112 (6.25%) |
3/111 (2.70%) |
3/107 (2.80%) |
5/109 (4.59%) |
Fatigue |
93/112 (83.04%) |
91/111 (81.98%) |
76/107 (71.03%) |
82/109 (75.23%) |
Insomnia |
18/112 (16.07%) |
15/111 (13.51%) |
15/107 (14.02%) |
28/109 (25.69%) |
Pain - Other |
7/112 (6.25%) |
12/111 (10.81%) |
11/107 (10.28%) |
6/109 (5.50%) |
Pain: Urethra |
0/112 (0.00%) |
3/111 (2.70%) |
0/107 (0.00%) |
3/109 (2.75%) |
Pain: Perineum |
0/112 (0.00%) |
2/111 (1.80%) |
1/107 (0.93%) |
1/109 (0.92%) |
Pain: Pelvis |
8/112 (7.14%) |
15/111 (13.51%) |
11/107 (10.28%) |
13/109 (11.93%) |
Pain: Breast |
2/112 (1.79%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Vagina |
3/112 (2.68%) |
5/111 (4.50%) |
2/107 (1.87%) |
2/109 (1.83%) |
Pain: Chest /Thorax Nos |
7/112 (6.25%) |
3/111 (2.70%) |
6/107 (5.61%) |
3/109 (2.75%) |
Pain: Chest Wall |
2/112 (1.79%) |
4/111 (3.60%) |
2/107 (1.87%) |
5/109 (4.59%) |
Pain: Throat/Pharynx/Larynx |
2/112 (1.79%) |
1/111 (0.90%) |
4/107 (3.74%) |
6/109 (5.50%) |
Pain: Pleura |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Pain: Head/Headache |
12/112 (10.71%) |
26/111 (23.42%) |
17/107 (15.89%) |
21/109 (19.27%) |
Pain: Neck |
0/112 (0.00%) |
5/111 (4.50%) |
1/107 (0.93%) |
1/109 (0.92%) |
Pain: Extremity-Limb |
26/112 (23.21%) |
18/111 (16.22%) |
18/107 (16.82%) |
18/109 (16.51%) |
Pain: Buttock |
3/112 (2.68%) |
3/111 (2.70%) |
0/107 (0.00%) |
3/109 (2.75%) |
Pain: Back |
25/112 (22.32%) |
23/111 (20.72%) |
16/107 (14.95%) |
22/109 (20.18%) |
Pain: Joint |
17/112 (15.18%) |
24/111 (21.62%) |
23/107 (21.50%) |
24/109 (22.02%) |
Pain: Bone |
7/112 (6.25%) |
12/111 (10.81%) |
15/107 (14.02%) |
9/109 (8.26%) |
Pain: Kidney |
2/112 (1.79%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Pain: Bladder |
5/112 (4.46%) |
2/111 (1.80%) |
3/107 (2.80%) |
3/109 (2.75%) |
Pain: Pain Nos |
4/112 (3.57%) |
8/111 (7.21%) |
3/107 (2.80%) |
4/109 (3.67%) |
Pain: Stomach |
1/112 (0.89%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Rectum |
2/112 (1.79%) |
6/111 (5.41%) |
1/107 (0.93%) |
8/109 (7.34%) |
Pain: Peritoneum |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Oral Cavity |
0/112 (0.00%) |
3/111 (2.70%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Dental/Teeth/Peridontal |
2/112 (1.79%) |
2/111 (1.80%) |
1/107 (0.93%) |
0/109 (0.00%) |
Pain: Abdominal Pain Nos |
41/112 (36.61%) |
38/111 (34.23%) |
30/107 (28.04%) |
33/109 (30.28%) |
Pain: Scalp |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Oral - Gums |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Pain: Skin |
1/112 (0.89%) |
0/111 (0.00%) |
2/107 (1.87%) |
0/109 (0.00%) |
Pain: Middle Ear |
1/112 (0.89%) |
3/111 (2.70%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: External Ear |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Cardiac/ Heart |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pain: Tumor |
2/112 (1.79%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Pain: Muscle |
21/112 (18.75%) |
17/111 (15.32%) |
21/107 (19.63%) |
25/109 (22.94%) |
Pain: Neuralgia |
2/112 (1.79%) |
1/111 (0.90%) |
3/107 (2.80%) |
0/109 (0.00%) |
Pain: Sinus |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
3/109 (2.75%) |
Syndromes - Other |
1/112 (0.89%) |
0/111 (0.00%) |
2/107 (1.87%) |
0/109 (0.00%) |
Cytokine Release Syndrome |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Flu-Like Syndrome |
0/112 (0.00%) |
4/111 (3.60%) |
1/107 (0.93%) |
1/109 (0.92%) |
Hepatobiliary disorders |
|
|
|
|
Hepatobiliary/Pancreas - Other |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Pancreatitis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Immune system disorders |
|
|
|
|
Allergic Reaction/Hypersensitivity |
19/112 (16.96%) |
20/111 (18.02%) |
5/107 (4.67%) |
4/109 (3.67%) |
Rhinitis |
6/112 (5.36%) |
11/111 (9.91%) |
5/107 (4.67%) |
10/109 (9.17%) |
Infections and infestations |
|
|
|
|
Inf W/Gr 3 Or 4 Anc: Blood |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Gr 3 Or 4 Anc: Dental-Tooth |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Skin (Cellulitis) |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: External Ear |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Vulva |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Upper Airway Nos |
0/112 (0.00%) |
5/111 (4.50%) |
3/107 (2.80%) |
4/109 (3.67%) |
Inf W/Gr 3 Or 4 Anc: Lip/Perioral |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Lung(Pneumonia) |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Joint |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Blood |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Wound |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Oral Cavity-Gums |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Otitis Media Nos |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Skin(Cellulitis) |
2/112 (1.79%) |
4/111 (3.60%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Catheter-Related |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Febrile Neutropenia |
4/112 (3.57%) |
2/111 (1.80%) |
2/107 (1.87%) |
4/109 (3.67%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Lip/Perioral |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf Unknown Anc: Nerve-Peripheral |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf Unknown Anc: Lung (Pneumonia) |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
2/109 (1.83%) |
Inf Unknown Anc: Sinus |
2/112 (1.79%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Dental-Tooth |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
3/109 (2.75%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Colon |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Urinary Tract Nos |
7/112 (6.25%) |
17/111 (15.32%) |
11/107 (10.28%) |
15/109 (13.76%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Abdomen Nos |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Infection - Other |
3/112 (2.68%) |
6/111 (5.41%) |
6/107 (5.61%) |
6/109 (5.50%) |
Colitis, Infectious (Eg.C. Difficile) |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Nerve-Peripheral |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Oral Cavity-Gums |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Conjunctiva |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf Unknown Anc: Vagina |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Bronchus |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Mucosa |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf Unknown Anc: Upper Airway Nos |
0/112 (0.00%) |
1/111 (0.90%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Pharynx |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Vagina |
0/112 (0.00%) |
0/111 (0.00%) |
4/107 (3.74%) |
1/109 (0.92%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Sinus |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
3/109 (2.75%) |
Inf Unknown Anc: Bronchus |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Inf Unknown Anc: Eye Nos |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf Unknown Anc: Urinary Tract Nos |
3/112 (2.68%) |
6/111 (5.41%) |
7/107 (6.54%) |
8/109 (7.34%) |
Inf Unknown Anc: Bladder (Urinary) |
0/112 (0.00%) |
0/111 (0.00%) |
2/107 (1.87%) |
1/109 (0.92%) |
Inf Unknown Anc: Wound |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf Unknown Anc: Dental-Tooth |
0/112 (0.00%) |
2/111 (1.80%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Vulva |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Pelvis Nos |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Upper Airway Nos |
0/112 (0.00%) |
0/111 (0.00%) |
2/107 (1.87%) |
2/109 (1.83%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Anal/Perianal |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Sinus |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
2/109 (1.83%) |
Inf W/Gr 3 Or 4 Anc: Pharynx |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Bronchus |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Ureter |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Kidney |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Gr 3 Or 4 Anc: Lymphatic |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Inf W/Nml Or Gr 1 Or 2 Anc: Bladder |
2/112 (1.79%) |
4/111 (3.60%) |
1/107 (0.93%) |
1/109 (0.92%) |
Inf W/Gr 3 Or 4 Anc: Urinary Tract Nos |
2/112 (1.79%) |
3/111 (2.70%) |
6/107 (5.61%) |
4/109 (3.67%) |
Inf W/Gr 3 Or 4 Anc: Catheter-Related |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Metabolism and nutrition disorders |
|
|
|
|
Ast |
6/112 (5.36%) |
17/111 (15.32%) |
9/107 (8.41%) |
7/109 (6.42%) |
Gfr |
1/112 (0.89%) |
3/111 (2.70%) |
3/107 (2.80%) |
1/109 (0.92%) |
Metabolic/Laboratory - Other |
5/112 (4.46%) |
3/111 (2.70%) |
6/107 (5.61%) |
4/109 (3.67%) |
Alkalosis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Proteinuria |
4/112 (3.57%) |
16/111 (14.41%) |
3/107 (2.80%) |
7/109 (6.42%) |
Hemoglobinuria |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
2/109 (1.83%) |
Creatinine |
16/112 (14.29%) |
24/111 (21.62%) |
6/107 (5.61%) |
11/109 (10.09%) |
Hypoalbuminemia |
13/112 (11.61%) |
19/111 (17.12%) |
11/107 (10.28%) |
16/109 (14.68%) |
Ggt |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Alt |
7/112 (6.25%) |
15/111 (13.51%) |
5/107 (4.67%) |
5/109 (4.59%) |
Alkaline Phosphatase |
15/112 (13.39%) |
21/111 (18.92%) |
11/107 (10.28%) |
11/109 (10.09%) |
Bilirubin |
3/112 (2.68%) |
4/111 (3.60%) |
1/107 (0.93%) |
2/109 (1.83%) |
Lipase |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Hypermagnesemia |
3/112 (2.68%) |
4/111 (3.60%) |
2/107 (1.87%) |
3/109 (2.75%) |
Hypophosphatemia |
2/112 (1.79%) |
8/111 (7.21%) |
3/107 (2.80%) |
2/109 (1.83%) |
Hyponatremia |
11/112 (9.82%) |
24/111 (21.62%) |
10/107 (9.35%) |
17/109 (15.60%) |
Hyperuricemia |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hypertriglyceridemia |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Bicarbonate, Serum-Low |
2/112 (1.79%) |
6/111 (5.41%) |
1/107 (0.93%) |
1/109 (0.92%) |
Amylase |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Hypernatremia |
1/112 (0.89%) |
3/111 (2.70%) |
2/107 (1.87%) |
1/109 (0.92%) |
Hypocalcemia |
17/112 (15.18%) |
21/111 (18.92%) |
7/107 (6.54%) |
11/109 (10.09%) |
Hyperkalemia |
8/112 (7.14%) |
9/111 (8.11%) |
2/107 (1.87%) |
4/109 (3.67%) |
Hyperglycemia |
24/112 (21.43%) |
27/111 (24.32%) |
19/107 (17.76%) |
29/109 (26.61%) |
Hypokalemia |
18/112 (16.07%) |
24/111 (21.62%) |
12/107 (11.21%) |
16/109 (14.68%) |
Hypoglycemia |
2/112 (1.79%) |
5/111 (4.50%) |
1/107 (0.93%) |
4/109 (3.67%) |
Hypercalcemia |
5/112 (4.46%) |
3/111 (2.70%) |
4/107 (3.74%) |
5/109 (4.59%) |
Hypomagnesemia |
29/112 (25.89%) |
40/111 (36.04%) |
6/107 (5.61%) |
13/109 (11.93%) |
Musculoskeletal and connective tissue disorders |
|
|
|
|
Musculoskeletal/St: Other |
0/112 (0.00%) |
3/111 (2.70%) |
1/107 (0.93%) |
1/109 (0.92%) |
Joint-Function |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Fracture |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Extremity-Upper (Function) |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Gait/Walking |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Arthritis |
1/112 (0.89%) |
2/111 (1.80%) |
0/107 (0.00%) |
2/109 (1.83%) |
Muscle Weakness - Whole Body/Generalized |
14/112 (12.50%) |
12/111 (10.81%) |
7/107 (6.54%) |
15/109 (13.76%) |
Muscle Weakness - Extremity-Upper |
2/112 (1.79%) |
1/111 (0.90%) |
2/107 (1.87%) |
0/109 (0.00%) |
Muscle Weakness - Extremity-Lower |
3/112 (2.68%) |
7/111 (6.31%) |
3/107 (2.80%) |
3/109 (2.75%) |
Nervous system disorders |
|
|
|
|
Syncope |
2/112 (1.79%) |
1/111 (0.90%) |
3/107 (2.80%) |
4/109 (3.67%) |
Involuntary Movement |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Psychosis |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Neurology - Other |
4/112 (3.57%) |
1/111 (0.90%) |
0/107 (0.00%) |
3/109 (2.75%) |
Encephalopathy |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Mood Alteration - Depression |
19/112 (16.96%) |
16/111 (14.41%) |
14/107 (13.08%) |
13/109 (11.93%) |
Mood Alteration - Anxiety |
14/112 (12.50%) |
20/111 (18.02%) |
9/107 (8.41%) |
16/109 (14.68%) |
Mood Alteration - Agitation |
2/112 (1.79%) |
3/111 (2.70%) |
1/107 (0.93%) |
1/109 (0.92%) |
Tremor |
1/112 (0.89%) |
2/111 (1.80%) |
1/107 (0.93%) |
1/109 (0.92%) |
Speech Impairment |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
2/109 (1.83%) |
Seizure |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Personality |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Irritability |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Somnolence |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cognitive Disturbance |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Ataxia |
2/112 (1.79%) |
2/111 (1.80%) |
3/107 (2.80%) |
1/109 (0.92%) |
Confusion |
3/112 (2.68%) |
4/111 (3.60%) |
0/107 (0.00%) |
1/109 (0.92%) |
Memory Impairment |
2/112 (1.79%) |
2/111 (1.80%) |
3/107 (2.80%) |
5/109 (4.59%) |
Dizziness |
13/112 (11.61%) |
9/111 (8.11%) |
10/107 (9.35%) |
11/109 (10.09%) |
Neuropathy,cranial - Cn Viii Hearing/Balance |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Neuropathy,cranial - Cn Ii Vision |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Neuropathy,cranial - Cn I Smell |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Neuropathy-Sensory |
76/112 (67.86%) |
64/111 (57.66%) |
63/107 (58.88%) |
71/109 (65.14%) |
Neuropathy-Motor |
7/112 (6.25%) |
2/111 (1.80%) |
4/107 (3.74%) |
4/109 (3.67%) |
Renal and urinary disorders |
|
|
|
|
Renal/Genitourinary - Other |
3/112 (2.68%) |
6/111 (5.41%) |
5/107 (4.67%) |
4/109 (3.67%) |
Leak, Gu - Vagina |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Leak, Gu - Urethra |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Cystitis |
0/112 (0.00%) |
3/111 (2.70%) |
3/107 (2.80%) |
3/109 (2.75%) |
Urinary Color Change |
1/112 (0.89%) |
2/111 (1.80%) |
3/107 (2.80%) |
2/109 (1.83%) |
Urinary Retention |
2/112 (1.79%) |
4/111 (3.60%) |
4/107 (3.74%) |
0/109 (0.00%) |
Urinary Electrolyte Wasting |
1/112 (0.89%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Obstruction, Gu - Ureter |
2/112 (1.79%) |
4/111 (3.60%) |
4/107 (3.74%) |
3/109 (2.75%) |
Incontinence, Urinary |
9/112 (8.04%) |
7/111 (6.31%) |
9/107 (8.41%) |
8/109 (7.34%) |
Fistula, Gu - Vagina |
3/112 (2.68%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Fistula, Gu - Bladder |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Bladder Spasm |
0/112 (0.00%) |
4/111 (3.60%) |
2/107 (1.87%) |
2/109 (1.83%) |
Renal Failure |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Urinary Frequency |
10/112 (8.93%) |
11/111 (9.91%) |
7/107 (6.54%) |
8/109 (7.34%) |
Reproductive system and breast disorders |
|
|
|
|
Libido |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Irregular Menses |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vaginal Dryness |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Sexual/Reproductive Function: Other |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Vaginitis |
2/112 (1.79%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vaginal Stenosis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vaginal Discharge |
7/112 (6.25%) |
5/111 (4.50%) |
10/107 (9.35%) |
9/109 (8.26%) |
Respiratory, thoracic and mediastinal disorders |
|
|
|
|
Pulmonary: Other |
2/112 (1.79%) |
3/111 (2.70%) |
1/107 (0.93%) |
2/109 (1.83%) |
Airway Obstruction - Bronchus |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Nasal/Paranasal Reactions |
4/112 (3.57%) |
2/111 (1.80%) |
1/107 (0.93%) |
10/109 (9.17%) |
Bronchospasm |
0/112 (0.00%) |
2/111 (1.80%) |
1/107 (0.93%) |
2/109 (1.83%) |
Atelectasis |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Voice Changes |
1/112 (0.89%) |
8/111 (7.21%) |
1/107 (0.93%) |
10/109 (9.17%) |
Hypoxia |
1/112 (0.89%) |
2/111 (1.80%) |
3/107 (2.80%) |
0/109 (0.00%) |
Cough |
18/112 (16.07%) |
12/111 (10.81%) |
24/107 (22.43%) |
21/109 (19.27%) |
Pneumonitis |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Pleural Effusion |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dyspnea |
29/112 (25.89%) |
26/111 (23.42%) |
22/107 (20.56%) |
23/109 (21.10%) |
Skin and subcutaneous tissue disorders |
|
|
|
|
Nail Changes |
2/112 (1.79%) |
5/111 (4.50%) |
3/107 (2.80%) |
6/109 (5.50%) |
Injection Site Reaction |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hair Loss/Alopecia (Scalp Or Body) |
69/112 (61.61%) |
65/111 (58.56%) |
69/107 (64.49%) |
71/109 (65.14%) |
Erythema Multiforme |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hypopigmentation |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Wound Complication, Non-Infectious |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
3/109 (2.75%) |
Bruising |
4/112 (3.57%) |
3/111 (2.70%) |
4/107 (3.74%) |
4/109 (3.67%) |
Acne |
0/112 (0.00%) |
2/111 (1.80%) |
1/107 (0.93%) |
2/109 (1.83%) |
Rash |
14/112 (12.50%) |
13/111 (11.71%) |
16/107 (14.95%) |
18/109 (16.51%) |
Dry Skin |
4/112 (3.57%) |
4/111 (3.60%) |
6/107 (5.61%) |
4/109 (3.67%) |
Decubitus |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Pruritus |
11/112 (9.82%) |
6/111 (5.41%) |
5/107 (4.67%) |
5/109 (4.59%) |
Burn |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
1/109 (0.92%) |
Urticaria |
1/112 (0.89%) |
2/111 (1.80%) |
0/107 (0.00%) |
0/109 (0.00%) |
Flushing |
5/112 (4.46%) |
3/111 (2.70%) |
4/107 (3.74%) |
2/109 (1.83%) |
Hand-Foot |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Dermatology/Skin - Other |
5/112 (4.46%) |
7/111 (6.31%) |
4/107 (3.74%) |
4/109 (3.67%) |
Hyperpigmentation |
0/112 (0.00%) |
7/111 (6.31%) |
0/107 (0.00%) |
3/109 (2.75%) |
Ulceration |
0/112 (0.00%) |
2/111 (1.80%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vascular disorders |
|
|
|
|
Inr |
4/112 (3.57%) |
5/111 (4.50%) |
1/107 (0.93%) |
0/109 (0.00%) |
Coagulopathy - Other |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Ptt |
1/112 (0.89%) |
6/111 (5.41%) |
0/107 (0.00%) |
3/109 (2.75%) |
Hemorrhage, Gu - Urinary Nos |
6/112 (5.36%) |
7/111 (6.31%) |
3/107 (2.80%) |
8/109 (7.34%) |
Hemorrhage, Gu - Vagina |
16/112 (14.29%) |
14/111 (12.61%) |
10/107 (9.35%) |
10/109 (9.17%) |
Hemorrhage, Gu - Urethra |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage/Pulmonary - Lung |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage, Gi - Rectum |
3/112 (2.68%) |
8/111 (7.21%) |
6/107 (5.61%) |
10/109 (9.17%) |
Hemorrhage/Pulmonary - Respiratory Tract Nos |
0/112 (0.00%) |
0/111 (0.00%) |
1/107 (0.93%) |
0/109 (0.00%) |
Hemorrhage, Gi - Varices (Rectal) |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage/Pulmonary - Nose |
1/112 (0.89%) |
15/111 (13.51%) |
2/107 (1.87%) |
22/109 (20.18%) |
Hematoma |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage, Gi - Anus |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
2/109 (1.83%) |
Hemorrhage, Gu - Ureter |
1/112 (0.89%) |
1/111 (0.90%) |
1/107 (0.93%) |
1/109 (0.92%) |
Hemorrhage, Gi - Oral Cavity |
0/112 (0.00%) |
3/111 (2.70%) |
0/107 (0.00%) |
7/109 (6.42%) |
Hemorrhage, Gu - Kidney |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage, Gu - Bladder |
0/112 (0.00%) |
5/111 (4.50%) |
1/107 (0.93%) |
2/109 (1.83%) |
Hemorrhage, Gi - Colon |
0/112 (0.00%) |
0/111 (0.00%) |
0/107 (0.00%) |
1/109 (0.92%) |
Hemorrhage, Cns |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Hemorrhage/Bleeding - Other |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
1/109 (0.92%) |
Vascular - Other |
1/112 (0.89%) |
0/111 (0.00%) |
0/107 (0.00%) |
0/109 (0.00%) |
Vein Injury - Other Nos |
0/112 (0.00%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Thrombosis/Embolism (Vascular Access-Related) |
1/112 (0.89%) |
1/111 (0.90%) |
0/107 (0.00%) |
0/109 (0.00%) |
Thrombosis/Thrombus/Embolism |
2/112 (1.79%) |
12/111 (10.81%) |
3/107 (2.80%) |
6/109 (5.50%) |
Indicates events were collected by non-systematic assessment
Term from vocabulary, CTCAE (3.0)
|